Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response

Vaccine

Volumn 29, Issue 32, 2011, Pages 5313-5321

  Charles Niño, Claudia ^a   Pedroza Roldan, Cesar ^a   Viveros, Monica ^b   Gevorkian, Goar ^a   Manoutcharian, Karen ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b SECRETARÍA DE SALUD   (Mexico)

Author keywords

Antigenic variability; Epitope libraries; Epitope vaccine; HIV neutralization; Immunogen

Indexed keywords

EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY; PLASMID DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VARIABLE EPITOPE LIBRARY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; DATABASES, PROTEIN; EPITOPES; FEMALE; GENE LIBRARY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNE EVASION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79960340347     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.007     Document Type: Article

References (49)

1. Tobin G.J., Trujillo J.D., Bushnell R.V., Lin G., Chaudhuri A.R., Long J., et al. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008, 26(November 18 (49)):6189-6199.
2. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10(January (1)):11-23.
3. Barouch D.H., Korber B. HIV-1 vaccine development after STEP. Annu Rev Med 2010, 61:153-167.
4. Hoxie J.A. Toward an antibody-based HIV-1 vaccine. Annu Rev Med 2010, 61:135-152.
5. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15(August (8)):866-870.
6. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(October 9 (5950)):285-289.
7. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(August 13 (5993)):856-861.
8. Sather D.N., Stamatatos L. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 2010, 28(May 26 (Suppl. 2)):B8-12.
9. Zolla-Pazner S., Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 2010, 10(July (7)):527-535.
10. Burke V., Williams C., Sukumaran M., Kim S.S., Li H., Wang X.H., et al. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure 2009, 17(November 11 (11)):1538-1546.
11. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22(June (3)):358-366.
12. Bunnik E.M., Euler Z., Welkers M.R., Boeser-Nunnik B.D., Grijsen M.L., Prins J.M., et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med 2010, 16(September (9)):995-997.
13. Nandi A., Lavine C.L., Wang P., Lipchina I., Goepfert P.A., Shaw G.M., et al. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 2010, 396(January 20 (2)):339-348.
14. Jiang X., Burke V., Totrov M., Williams C., Cardoso T., Gorny M.K., et al. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol 2010, 17(August (8)):955-961.
15. Pedroza-Roldan C., Charles-Nino C., Saavedra R., Govezensky T., Vaca L., Avaniss-Aghajani E., et al. Variable epitope library-based vaccines: shooting moving targets. Mol Immunol 2009, 47(December (2-3)):270-282.
16. Manoutcharian K., Diaz-Orea A., Gevorkian G., Fragoso G., Acero G., Gonzalez E., et al. Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis. Vet Immunol Immunopathol 2004, 99(May (1-2)):11-24.
17. Gevorkian G., Manoutcharian K., Govezensky T., Cano J.A., Dominguez V., Santamaria H., et al. Identification of mimotopes of platelet autoantigens associated with autoimmune thrombocytopenic purpura. J Autoimmun 2000, 15(August (1)):33-40.
18. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003, 100(April 1 (7)):4144-4149.
19. Schweighardt B., Liu Y., Huang W., Chappey C., Lie Y.S., Petropoulos C.J., et al. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 2007, 46(September 1 (1)):1-11.
20. Persic L., Roberts A., Wilton J., Cattaneo A., Bradbury A., Hoogenboom H.R. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997, 187(March 10 (1)):9-18.
21. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17(July (7)):1055-1065.
22. Morrow M.P., Yan J., Pankhong P., Ferraro B., Lewis M.G., Khan A.S., et al. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol 2010, 17(October (10)):1493-1499.
23. Hirao L.A., Wu L., Khan A.S., Satishchandran A., Draghia-Akli R., Weiner D.B. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008, 26(January 17 (3)):440-448.
24. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33(October 29 (4)):542-554.
25. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R.T., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007, 13(January (1)):100-106.
26. Almond D., Kimura T., Kong X., Swetnam J., Zolla-Pazner S., Cardozo T. Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res Hum Retroviruses 2010, 26(June (6)):717-723.
27. Smith D.H., Winters-Digiacinto P., Mitiku M., O'Rourke S., Sinangil F., Wrin T., et al. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. PLoS One 2010, 5(8):e12076.
28. Gao F., Scearce R.M., Alam S.M., Hora B., Xia S., Hohm Y.E., et al. Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology 2009, 394(November 10 (1)):91-98.
29. Dieltjens T., Willems B., Coppens S., Van Nieuwenhove L., Humbert M., Dietrich U., et al. Unravelling the antigenic landscape of the HIV-1 subtype A envelope of an individual with broad cross-neutralizing antibodies using phage display peptide libraries. J Virol Methods 2010, 169(October (1)):95-102.
30. Humbert M., Antoni S., Brill B., Landersz M., Rodes B., Soriano V., et al. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur J Immunol 2007, 37(February (2)):501-515.
31. Humbert M., Rasmussen R.A., Ong H., Kaiser F.M., Hu S.L., Ruprecht R.M. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS One 2008, 3(12):e3937.
32. Mouquet H., Scheid J.F., Zoller M.J., Krogsgaard M., Ott R.G., Shukair S., et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467(September 30 (7315)):591-595.
33. Verkoczy L., Diaz M., Holl T.M., Ouyang Y.B., Bouton-Verville H., Alam S.M., et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A 2010, 107(January 5 (1)):181-186.
34. Ofek G., Guenaga F.J., Schief W.R., Skinner J., Baker D., Wyatt R., et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A 2010, 107(October 19 (42)):17880-17887.
35. Correia B.E., Ban Y.E., Holmes M.A., Ellingson K., Kraft Z., Carrico C., et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 2010, 18(September 8 (9)):1116-1126.
36. Nkolola J.P., Peng H., Settembre E.C., Freeman M., Grandpre L.E., Devoy C., et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 2010, 84(April (7)):3270-3279.
37. Bianchi E., Joyce J.G., Miller M.D., Finnefrock A.C., Liang X., Finotto M., et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 2010, 107(June 8 (23)):10655-10660.
38. Davis K.L., Gray E.S., Moore P.L., Decker J.M., Salomon A., Montefiori D.C., et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 2009, 387(May 10 (2)):414-426.
39. Blish C.A., Sather D.N., Sellhorn G., Stamatatos L., Sun Y., Srivastava I., et al. Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J Virol 2010, 84(March (5)):2573-2584.
40. Haynes B.F., Ma B., Montefiori D.C., Wrin T., Petropoulos C.J., Sutherland L.L., et al. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology 2006, 345(February 5 (1)):44-55.
41. Moseri A., Tantry S., Sagi Y., Arshava B., Naider F., Anglister J. An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120. Virology 2010, 401(June 5 (2)):293-304.
42. Zolla-Pazner S., Cohen S., Pinter A., Krachmarov C., Wrin T., Wang S., et al. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 2009, 392(September 15 (1)):82-93.
43. Zolla-Pazner S., Cohen S.S., Krachmarov C., Wang S., Pinter A., Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 2008, 372(March 15 (2)):233-246.
44. Totrov M., Jiang X., Kong X.P., et al. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology 2010, 405(September 30 (2)):513-523.
45. Zhang P.F., Cham F., Dong M., Choudhary A., Bouma P., Zhang Z., et al. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A 2007, 104(June 12 (24)):10193-10198.
46. Anderson D.E., Singapuri A., Kang K.H., Montefiori D.C., Torres J.V. Timing of retroviral infection influences anamnestic immune response in vaccinated primates. Viral Immunol 2005, 18(4):689-694.
47. Hewer R., Meyer D. Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits. Mol Immunol 2003, 40(October (6)):327-335.
48. Oliveira E., Jimenez-Clavero M.A., Nunez J.I., Sobrino F., Andreu D. Analysis of the immune response against mixotope peptide libraries from a main antigenic site of foot-and-mouth disease virus. Vaccine 2005, 23(April 8 (20)):2647-2657.
49. Azizi A., Anderson D.E., Torres J.V., Ogrel A., Ghorbani M., Soare C., et al. Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J Immunol 2008, 180(Febru 15 (4)):2174-2186.